Correspondence 0001493152-24-003313 from Processa Pharmaceuticals, Inc. (PCSA)

Processa Pharmaceuticals, Inc.
Date: Jan. 22, 2024 · CIK: 0001533743 · Accession: 0001493152-24-003313

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-276308

Date

January 24, 2024

Author

Chief

Form

CORRESP

Company

Processa Pharmaceuticals, Inc.

Letter

Re: Processa Pharmaceuticals, Inc.

January 22, 2024

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Registration Statement on Form S-1 (Registration No. 333-276308) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering pursuant to the registration statement on Form S-1 (333-276308) (the “Registration Statement”), hereby concurs in the request by Processa Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:15 P.M. Eastern Time on Wednesday, January 24, 2024, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

Very
truly yours,
H.C.
WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

January
22, 2024

VIA
FACSIMILE AND EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporate Finance

Washington,
DC 20549

    Re:
    Processa
    Pharmaceuticals, Inc.

    Registration
    Statement on Form S-1 (Registration No. 333-276308) -

    Concurrence
    in Acceleration Request

Ladies
and Gentlemen:

H.C.
Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering
pursuant to the registration statement on Form S-1 (333-276308) (the “Registration Statement”), hereby concurs in
the request by Processa Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to
5:15 P.M. Eastern Time on Wednesday, January 24, 2024, or as soon as practicable thereafter, pursuant to Rule 461 under the Securities
Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant
to the Registration Statement.

    Very
    truly yours,

    H.C.
    WAINWRIGHT & CO., LLC

    By:
    /s/
    Edward D. Silvera

    Name:
    Edward
    D. Silvera

    Title:
    Chief
    Operating Officer

430
Park Avenue | New York, NY 10022 | 212.356.0500 | www.hcwco.com

Member:
FINRA/SIPC

SecProbe.io